Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly A Struble

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
AIDS (London, England)|January 2, 2007
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patientsLisa K Naeger, Kimberly A Struble
AIDS (London, England)|March 22, 2006
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patientsLisa K Naeger, Kimberly A Struble
Current Opinion in HIV and AIDS|April 18, 2009
A regulatory perspective on the role of drug interactions in antiretroviral drug developmentKimberly A Struble, Kellie Schoolar Reynolds
Infection Control and Hospital Epidemiology|February 14, 2014
Reply to Tan et alDavid T Kuhar, Kimberly A Struble, David K Henderson
Current Opinion in HIV and AIDS|April 18, 2009
Regulatory issues in developing new HIV protease inhibitors: risks and benefitsKimberly A Struble, Kirk M Chan-Tack, Guoxing Greg Soon
AIDS Patient Care and Stds|November 26, 2008
Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting SystemKirk M Chan-Tack, Kimberly A Struble, Debra B Birnkrant
Journal of Clinical Pharmacology|June 30, 2011
Scientific considerations for pharmacoenhancers in antiretroviral therapyVikram Arya, Sarah M Robertson, Kimberly A Struble, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Long-Acting Formulations for the Prevention and Treatment of Human Immunodeficiency Virus (HIV)-1 Infection: Strategic Leveraging and Integration of Multidisciplinary Knowledge to Advance Public HealthVikram Arya, Aimee C Hodowanec, Stephanie B Troy, et al.
Antiviral Research|August 12, 2009
Running a tightrope: regulatory challenges in the development of antiretroviralsLisa K Naeger, Kimberly A Struble, Jeffrey S Murray, et al.
AIDS (London, England)|May 16, 2007
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting SystemKirk M Chan-Tack, Melissa M Truffa, Kimberly A Struble, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
AIDS (London, England)|January 2, 2007
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patientsLisa K Naeger, Kimberly A Struble
AIDS (London, England)|March 22, 2006
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patientsLisa K Naeger, Kimberly A Struble
Current Opinion in HIV and AIDS|April 18, 2009
A regulatory perspective on the role of drug interactions in antiretroviral drug developmentKimberly A Struble, Kellie Schoolar Reynolds
Infection Control and Hospital Epidemiology|February 14, 2014
Reply to Tan et alDavid T Kuhar, Kimberly A Struble, David K Henderson
Current Opinion in HIV and AIDS|April 18, 2009
Regulatory issues in developing new HIV protease inhibitors: risks and benefitsKimberly A Struble, Kirk M Chan-Tack, Guoxing Greg Soon
AIDS Patient Care and Stds|November 26, 2008
Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting SystemKirk M Chan-Tack, Kimberly A Struble, Debra B Birnkrant
Journal of Clinical Pharmacology|June 30, 2011
Scientific considerations for pharmacoenhancers in antiretroviral therapyVikram Arya, Sarah M Robertson, Kimberly A Struble, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Long-Acting Formulations for the Prevention and Treatment of Human Immunodeficiency Virus (HIV)-1 Infection: Strategic Leveraging and Integration of Multidisciplinary Knowledge to Advance Public HealthVikram Arya, Aimee C Hodowanec, Stephanie B Troy, et al.
Antiviral Research|August 12, 2009
Running a tightrope: regulatory challenges in the development of antiretroviralsLisa K Naeger, Kimberly A Struble, Jeffrey S Murray, et al.
AIDS (London, England)|May 16, 2007
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting SystemKirk M Chan-Tack, Melissa M Truffa, Kimberly A Struble, et al.
Pageof 2